Organon & Co.
OGN
Pozycja w akcjach
#4360
Organon & Co., a global pharmaceutical enterprise, is dedicated to developing... Organon & Co., a global pharmaceutical enterprise, is dedicated to developing and delivering a wide array of prescription therapies. Its women's health division features reproductive care products, encompassing birth control and fertility treatments, notably Nexplanon/Implanon, an extended-duration contraceptive. The company's biosimilars collection includes three immune-related medications (Brenzys, Renflexis, Hadlima) and two cancer therapies (Ontruzant, Aybintio). Additionally, Organon provides cardiovascular medications, such as cholesterol-reducing drugs (Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, Zocor) and treatments for high blood pressure (Cozaar, Hyzaar). Their respiratory product line addresses asthma symptoms with brands like Singulair, Dulera, Zenhale, and Asmanex, and manages seasonal allergies through Singulair, Nasonex, Clarinex, and Aerius. Furthermore, their offerings extend to dermatological care (Diprosone, Elocon), bone strengthening (Fosamax), and non-narcotic pain relief (Arcoxia, Diprospan, Celestone). The portfolio also comprises Proscar for treating symptomatic benign prostatic hyperplasia and Propecia for combating male pattern hair loss. The company's products are primarily distributed to pharmaceutical wholesalers, retailers, medical facilities, government entities, and various managed healthcare organizations, including health maintenance organizations and pharmacy benefit managers. Organon & Co. was established in 2020 and is headquartered in Jersey City, New Jersey.
Cena akcji
$13.76
Ostatnia synchronizacja: 2026-10-20
Kapitalizacja rynkowa
$3.61B
Zmiana (1 dzień)
0.07%
Zmiana (1 rok)
52.49%
Kraj
US
Handel Organon & Co. (OGN)
Kategoria
Healthcare
Przychody dla Organon & Co. (OGN)
Przychody w Jun 2026 TTM: $6.13B
Według najnowszych raportów finansowych Organon & Co., obecny przychód firmy (TTM) wynosi $6.13B. W roku 2024 firma osiągnęła przychód w wysokości $6.40B wzrost w porównaniu do przychodu z roku 2023, który wynosił $6.26B. Przychód to całkowita kwota dochodu generowana przez firmę ze sprzedaży towarów lub usług. W przeciwieństwie do zysku, nie są odliczane żadne koszty.
Historia przychodów firmy Organon & Co. od 2017 do 2026
Przychody na koniec każdego roku
| Rok | Przychody | Zmień |
|---|---|---|
| 2026 (TTM) | $6.13B | -1.43% |
| 2025 | $6.22B | -2.92% |
| 2024 | $6.40B | 2.24% |
| 2023 | $6.26B | 1.44% |
| 2022 | $6.17B | -2.06% |
| 2021 | $6.30B | -3.49% |
| 2020 | $6.53B | -16.01% |
| 2019 | $7.78B | -20.46% |
| 2018 | $9.78B | -6.89% |
| 2017 | $10.50B | 0.00% |
Przychody podobnych firm lub konkurentów
| Firma | Przychody | Różnica w przychodach | Kraj |
|---|---|---|---|
| $79.67B | 1,200.24% |
US
|
|
| $99.34B | 1,521.27% |
US
|
|
| $64.39B | 950.86% |
US
|
|
| $66.40B | 983.73% |
US
|
|
| $77.52B | 1,165.20% |
CH
|
